Saturday 17 October 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.48
0.12
−3.33%
Follow PASG
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 161.80 | 123.60 | 20.80 | 11.50 | 9.02 | 5.12 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 764.60 | 617.40 | 131.00 | 38.40 | 35.80 | 20.20 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 20 | 74 | 133 | 85 | 58 | 60 | 24 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (13) | (46) | (112) | (185) | (136) | (102) | (65) | (46) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (13) | (46) | (112) | (185) | (136) | (102) | (65) | (46) | |||||
| Depreciation | — | — | — | 0 | 1 | 4 | 4 | 2 | 2 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.28) | (215.46) | (58.20) | (69.60) | (50.00) | (37.20) | (21.40) | (14.35) | |||||
| Cash flow | — | — | (0.41) | (188.37) | (41.70) | (47.57) | (43.44) | (28.59) | (15.58) | (9.93) | |||||
| Capex | — | — | 0.00 | (7.99) | (0.85) | (9.61) | (1.94) | (0.05) | (0.01) | 0.37 | |||||
| Free cash flow | — | — | (0.41) | (196.36) | (42.56) | (57.18) | (45.37) | (28.65) | (15.59) | (9.56) | |||||
| Book value | — | — | (0.27) | (265.59) | 157.82 | 119.47 | 73.99 | 40.66 | 19.90 | 5.91 | |||||
| Shares, m | — | — | 46 | 0 | 2 | 3 | 3 | 3 | 3 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (19) | (40) | (81) | (127) | (118) | (78) | (48) | (32) | ||||
| Capex | — | — | (3) | (2) | (2) | (26) | (5) | 0 | 0 | 1 | |||||
| Free cash flow | — | — | (19) | (42) | (82) | (153) | (123) | (78) | (48) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 33 | 162 | 296 | 296 | 179 | 102 | 59 | 25 | ||||
| Total debt | — | — | — | — | — | — | 27 | — | — | — | |||||
| Net debt | — | — | (25) | (159) | (305) | (316) | (190) | (114) | (77) | (46) | |||||
| Shareholders’ equity | — | — | (12) | (56) | 305 | 319 | 201 | 111 | 61 | 19 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (76.33) | (43.04) | (44.31) | (54.28) | (45.48) | (51.80) | (51.21) | (55.28) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (4,024.99) | (735.76) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 37.32 | 133.38 | (90.34) | (59.48) | (52.35) | (65.29) | (75.07) | (113.78) | |||||
Negative figures in brackets.
Charts ten years each
Passage Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AEON AEON Biopharma, Inc. | $12.1M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| ASBP Aspire-Lakewood Holdings, Inc. | $12.1M | 0.2× | — | — | n/m | −85.54% (below 0%: shrinking) | (47.70%) | (4,244.37%) | Compare |
| ACTU Actuate Therapeutics, Inc. | $12.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| PLUR Pluri Inc. | $11.9M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | |
| PTN Palatin Technologies, Inc. | $11.6M | — (loss-making) | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| CLRB Cellectar Biosciences, Inc. | $11.2M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $11.8M | — | — | −15.46% | — | −3.42% | 29.26% | (110.64%) |
Passage Bio, Inc. (PASG) key facts
- Concern: Passage Bio, Inc. reported a net loss of $45.5 million, or a loss of $14.35 per share, for fiscal 2025.
- Passage Bio, Inc. (PASG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PASG traded at $3.48, a market capitalization of $11.6 million.
- Return on equity was −113.8% and debt-to-equity 0.00.